Protalix BioTherapeutics (PLX) Reports Q1 Loss of $0.05
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.72 +1.87%
Revenue Growth %: -15.8%
Financial Fact:
OPERATING LOSS: -6.65M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: -15.8%
Financial Fact:
OPERATING LOSS: -6.65M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q1 EPS of ($0.05). Revenue for the quarter came in at $16.1 million versus the consensus estimate of $15.5 million.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oracle reports earnings today: AI spending bet faces its toughest test yet
- DA Davidson Reiterates Buy Rating on EVI Industries Inc. (EVI) Following Q4 Results
- Academy Sports & Outdoors Inc. (ASO) PT Raised to $47 at BMO Capital
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
